LOS ANGELES, July 28, 2026 /PRNewswire/ — Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. (“ADMA” or “the Company”) (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
If you purchased ADMA Biologics, Inc. securities you may be entitled to compensation without payment of any out-of-pocket fees or costs. Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact SBS to find out if they are eligible to recover their losses or lead this lawsuit. Appointment as lead plaintiff is not required to partake in any recovery. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
CLASS PERIOD: August 9, 2024 to March 25, 2026
DEADLINE: August 10, 2026
If you are a shareholder who suffered a loss, click here to participate.
Details of the Case: According to the Complaint, the Company made false and misleading statements to the market. ADMA engaged in a related party transaction it failed to disclose. The Company utilized channel stuffing to create the appearance of revenue. The Company failed to maintain appropriate internal controls. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about ADMA, investors suffered damages.
We encourage investors to contact Adam Rosen and David Schwartz of Schall Brown & Schwartz, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
Why SBS: Schall Brown & Schwartz represents investors around the world, specializing in securities class action lawsuits and shareholder rights litigation. SBS brings together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz. SBS attorneys and co-counsel are responsible for recovering over a billion dollars for violations of securities laws and corporate misfeasance.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall Brown & Schwartz LLP
Brian Schall, Esq.,
Adam Rosen, Esq.,
David Schwartz, Esq.,
Office: 310-301-3335
View original content:https://www.prnewswire.com/news-releases/adma-biologics-inc-investor-alert-contact-sbs-by-august-10-2026-for-opportunity-to-lead-securities-fraud-lawsuit-302835891.html
SOURCE Schall, Brown & Schwartz LLP
